Pharmaceutical companies are under increasing pressure to modernize labeling processes and prepare for electronic product information (ePI) requirements. Yet many organizations searching for “recommended tools for structured product labeling updates” quickly discover that selecting the wrong platform can create costly implementation delays, fragmented workflows, compliance risks, and long-term operational inefficiencies. The challenge is no longer only regulatory — it is strategic.
Most companies begin by searching for an electronic product information vendor or comparing different ePI vendor solutions. However, choosing a tool without first understanding internal processes, regulatory maturity, global market requirements, and future digital goals often leads to poor implementation outcomes. A tool that works for one pharmaceutical company may be completely unsuitable for another.
This is where independent ePI consultancy becomes critical. Before selecting an electronic product information vendor, companies should work with experienced Subject Matter Experts (SMEs) who understand regulatory operations, structured product labeling, FHIR-based ePI standards, lifecycle management, and vendor ecosystems. Successful ePI implementation requires much more than software selection, it requires strategic alignment between business objectives, regulatory expectations, and digital transformation readiness.
At Billev Pharma East, we help pharmaceutical companies evaluate structured product labeling tools objectively and identify the right implementation strategy before investing in an ePI vendor. As an independent consultancy with strong expertise in electronic product information implementation, we act as the bridge between pharma companies and software vendors — helping organizations reduce risk, improve compliance readiness, and choose solutions aligned with their long-term goals.
What pharmaceutical companies are struggling with when choosing structured product labeling tools
Many pharmaceutical companies searching for “recommended tools for structured product labeling updates” believe the biggest challenge is finding the right software. In reality, the biggest challenge is understanding which solution truly fits their regulatory processes, global operations, long-term digital strategy, and evolving ePI requirements.
The pressure around ePI implementation is growing rapidly. Regulatory teams are expected to modernize labeling workflows while managing fragmented systems, disconnected data, inconsistent governance, and increasing compliance expectations. At the same time, leadership teams are under pressure to invest in the “right” technology quickly — often before internal processes are fully prepared for future ePI requirements and structured product labeling obligations. This creates uncertainty, delays, and expensive decision-making mistakes.
Many organizations start comparing different electronic product information vendor solutions without fully understanding how structured content, FHIR standards, multilingual requirements, lifecycle management, and regional ePI requirements will affect daily operations. As a result, companies often invest in tools that create additional complexity instead of simplifying regulatory processes.
The reality is that selecting an ePI vendor is not simply a procurement decision. It is a strategic transformation initiative that impacts regulatory affairs, quality, pharmacovigilance, IT, and global operations simultaneously. Without the right preparation and expert guidance, companies risk choosing platforms that do not support future scalability, compliance readiness, or evolving global ePI requirements. This is why pharmaceutical companies should first work with independent ePI SMEs before selecting a vendor. The right consultancy partner helps organizations evaluate their real needs, reduce implementation risk, and choose structured product labeling tools aligned with both compliance requirements and long-term business goals.
Why FHIR standards are becoming critical for future ePI implementation
One of the biggest mistakes pharmaceutical companies make when evaluating an electronic product information vendor is focusing only on current document management needs instead of future interoperability requirements. The EU ePI initiative is heavily connected to FHIR (Fast Healthcare Interoperability Resources) standards, which are becoming the foundation for structured, machine-readable product information across Europe. This means that future ePI systems will no longer function as isolated document repositories. They will increasingly need to exchange data with regulatory systems, healthcare platforms, pharmacovigilance environments, and digital health applications. For pharmaceutical companies, this changes the entire vendor selection process.
An ePI vendor that appears technically strong today may create major scalability problems later if its platform cannot support evolving FHIR requirements, structured content reuse, API connectivity, multilingual data models, or future interoperability expectations defined by EMA and the European Medicines Regulatory Network. This is why structured product labeling projects should not start with software demonstrations. They should start with a clear assessment of long-term digital architecture and regulatory readiness.
At Billev Pharma East, our SMEs help pharmaceutical companies evaluate whether vendor solutions are truly aligned with future FHIR-based ePI expectations. We assess how different platforms approach structured data models, lifecycle management, interoperability, governance, and integration across regulatory operations before companies commit to long-term implementation investments. This allows organizations to avoid costly migrations, duplicated implementation work, and future compliance limitations as ePI requirements continue to evolve globally.
How Billev Pharma East supports ePI implementation before vendor selection
Most pharmaceutical companies assume the implementation challenge begins after selecting an electronic product information vendor. In reality, many of the biggest risks appear much earlier — during preparation, governance definition, and vendor evaluation.
This is where Billev Pharma East provides both strategic advisory support and practical implementation guidance tailored to regulated pharmaceutical environments. Our support typically starts with an assessment of the company’s current regulatory and labeling maturity. We evaluate existing labeling workflows, document governance, lifecycle management processes, multilingual requirements, data ownership structures, and digital readiness for structured product labeling transformation. Based on this assessment, we perform a gap analysis that identifies operational, regulatory, and technical risks that could negatively impact future ePI implementation. This often includes fragmented content management, disconnected regulatory systems, inconsistent global labeling processes, or insufficient governance structures.
In practice, our consultancy process is typically structured in several phases. We begin with an evaluation of the company’s current labeling landscape, governance model, and regulatory workflows. This is followed by a gap analysis focused on structured content readiness, FHIR compatibility, lifecycle management processes, and global operational requirements. Based on these findings, we help organizations define implementation priorities, establish realistic governance structures, and create vendor evaluation criteria aligned with their long-term ePI strategy. Once the gaps are identified, our SMEs help companies define realistic implementation priorities and vendor evaluation criteria. Instead of comparing platforms based on generic software demonstrations, pharmaceutical organizations gain a structured decision-making framework based on their actual operational needs.
We also support vendor assessment activities directly. This includes evaluating how different ePI vendor solutions manage FHIR compatibility, structured content reuse, lifecycle updates, multilingual product information, integration capabilities, and long-term scalability across global markets.
Because Billev Pharma East operates independently from software providers, our recommendations remain fully objective and focused on what best supports the company’s future regulatory operations.The result is a significantly lower implementation risk, faster decision-making, and a much clearer path toward sustainable ePI transformation.
Companies preparing for ePI transformation often discover that the biggest implementation risks appear long before software deployment begins. Speaking with experienced ePI SMEs early helps organizations avoid costly vendor decisions and build a much clearer implementation roadmap.
Our multidisciplinary team combines expertise across regulatory affairs, pharmacovigilance, quality systems, structured content governance, and digital transformation projects within regulated pharmaceutical environments.
What matters most when preparing for structured product labeling updates
Successful structured product labeling implementation is not only about technology — it is about preparation. Many pharmaceutical companies begin searching for an electronic product information vendor too late in the process, when internal systems, governance structures, and regulatory workflows are still unprepared for ePI transformation. This often leads to delays, inefficient implementations, and tools that fail to support long-term operational goals.
One of the most important factors is understanding that every company has different regulatory and business needs. Organizations operating across multiple regions face very different challenges compared to companies focused only on EU markets. Multilingual requirements, regional compliance expectations, lifecycle management complexity, and integration with existing regulatory systems all influence which ePI vendor solution will be the right fit.
Preparation also requires realistic evaluation of internal processes. Many companies still rely on fragmented labeling workflows, disconnected content ownership, and manual document handling. Without proper strategic alignment, even the most advanced structured product labeling tool will struggle to deliver value.
This is why companies should focus first on readiness, governance, scalability, and long-term digital strategy before selecting an electronic product information vendor. Choosing a platform without expert guidance can create years of operational inefficiencies and expensive process corrections later.
At Billev Pharma East, we help pharmaceutical organizations prepare for structured product labeling updates from both a regulatory and operational perspective. Our SMEs help companies understand their true requirements, evaluate implementation priorities, and identify which solutions align with their future goals before any vendor selection takes place. This allows organizations to move forward with confidence, lower risk, and a much clearer implementation strategy.
Why global pharmaceutical companies face additional ePI complexity
Not all pharmaceutical companies face the same structured product labeling challenges. Organizations operating globally often underestimate how different regional requirements can significantly affect ePI implementation strategy.
While the EU is moving toward harmonized FHIR-based electronic product information standards through the EMA initiative, other regions continue using different structured labeling frameworks, submission models, and regulatory expectations.
This creates a major operational challenge for companies managing product information across multiple markets simultaneously. Global pharmaceutical organizations must consider how their ePI vendor solution handles multilingual content management, regional submission variations, lifecycle synchronization, local health authority requirements, and interoperability across separate regulatory ecosystems. Without proper strategic planning, companies risk creating disconnected regional processes that increase maintenance burden, duplicate labeling activities, and reduce long-term scalability.
At Billev Pharma East, we help pharmaceutical companies evaluate structured product labeling strategies from a global operational perspective. Our SMEs support organizations in identifying where regional harmonization is possible, where local adaptations are required, and how vendor capabilities align with long-term international expansion goals.
This helps companies avoid building fragmented ePI environments that become difficult and expensive to maintain over time.
Why independent ePI expertise reduces long-term implementation risk
One of the most overlooked challenges in structured product labeling projects is the assumption that software alone guarantees successful implementation. In reality, many pharmaceutical companies discover too late that even the best-looking electronic product information vendor solution cannot compensate for unclear governance, poorly defined processes, or lack of internal alignment. This is where implementation risk becomes a serious business problem.
Choosing the wrong structured product labeling approach can lead to costly process redesigns, delayed regulatory readiness, inefficient content management, and significant operational burden across regulatory affairs, quality, and IT teams. For global pharmaceutical companies, the risk becomes even greater when regional requirements, multilingual labeling obligations, and scalability expectations are not considered early enough. Many organizations also underestimate how different vendor solutions approach lifecycle management, interoperability, structured content governance, and future ePI expansion. Without independent guidance, companies often make decisions based primarily on software demonstrations instead of real operational fit.
At Billev Pharma East, we help organizations approach structured product labeling as a sustainable operational transformation — not just a software implementation project. Our consultancy support allows pharmaceutical companies to move forward with greater confidence, lower implementation risk, and a clearer understanding of which ePI strategy will deliver long-term value across their organization.
Choosing the right ePI strategy starts before software selection
As electronic product information requirements continue to evolve, pharmaceutical companies can no longer afford reactive implementation decisions or vendor-driven strategies without internal preparation. Choosing the right electronic product information vendor is not simply a software procurement exercise. It is a long-term operational transformation that affects regulatory affairs, labeling governance, quality systems, pharmacovigilance, and future digital scalability across the organization.
Companies that invest time in strategic preparation before vendor selection are significantly better positioned to reduce implementation risk, accelerate adoption, and avoid costly operational redesigns later.
At Billev Pharma East, we help pharmaceutical organizations prepare for structured product labeling transformation through independent ePI consultancy, regulatory expertise, and practical implementation guidance tailored to real operational needs.
If your organization is currently evaluating recommended tools for structured product labeling updates or searching for the right ePI vendor, contact Billev Pharma East to discuss your current labeling landscape, evaluate your ePI readiness, and identify which structured product labeling strategy best supports your long-term regulatory and operational goals.
Sources: 1 – European Medicines Agency (EMA). (n.d.). Electronic Product Information (ePI), 2 – U.S. Food and Drug Administration (FDA). (n.d.). Structured Product Labeling Resources, 3 – European Commission. (n.d.). Pharmaceutical Strategy for Europe, 4 – European Medicines Regulatory Network (EMRN). (n.d.). ePI FHIR Implementation Guide.
Image credits:
In-article images: Freepik
In-article images: Freepik
Hero image: Freepik